CN105853422A - 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法 - Google Patents

联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法 Download PDF

Info

Publication number
CN105853422A
CN105853422A CN201610252021.1A CN201610252021A CN105853422A CN 105853422 A CN105853422 A CN 105853422A CN 201610252021 A CN201610252021 A CN 201610252021A CN 105853422 A CN105853422 A CN 105853422A
Authority
CN
China
Prior art keywords
dmf
laquinimod
amount
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610252021.1A
Other languages
English (en)
Chinese (zh)
Inventor
约珥·弗拉克斯曼·凯耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN105853422A publication Critical patent/CN105853422A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Liquid Crystal Substances (AREA)
CN201610252021.1A 2012-03-27 2013-03-26 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法 Pending CN105853422A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616337P 2012-03-27 2012-03-27
US61/616,337 2012-03-27
US13/800,047 US20130259856A1 (en) 2012-03-27 2013-03-13 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US13/800,047 2013-03-13
CN201380016933.3A CN104470520A (zh) 2012-03-27 2013-03-26 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380016933.3A Division CN104470520A (zh) 2012-03-27 2013-03-26 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法

Publications (1)

Publication Number Publication Date
CN105853422A true CN105853422A (zh) 2016-08-17

Family

ID=49235339

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610252021.1A Pending CN105853422A (zh) 2012-03-27 2013-03-26 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法
CN201380016933.3A Pending CN104470520A (zh) 2012-03-27 2013-03-26 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380016933.3A Pending CN104470520A (zh) 2012-03-27 2013-03-26 联合使用拉喹莫德和富马酸二甲酯治疗多发性硬化症的方法

Country Status (17)

Country Link
US (6) US20130259856A1 (cg-RX-API-DMAC10.html)
EP (1) EP2830623A4 (cg-RX-API-DMAC10.html)
JP (2) JP2015512406A (cg-RX-API-DMAC10.html)
KR (1) KR20150003765A (cg-RX-API-DMAC10.html)
CN (2) CN105853422A (cg-RX-API-DMAC10.html)
AR (1) AR090491A1 (cg-RX-API-DMAC10.html)
AU (2) AU2013239850A1 (cg-RX-API-DMAC10.html)
CA (1) CA2868259A1 (cg-RX-API-DMAC10.html)
EA (1) EA201491773A1 (cg-RX-API-DMAC10.html)
HK (1) HK1205941A1 (cg-RX-API-DMAC10.html)
IL (1) IL234687A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014011616A (cg-RX-API-DMAC10.html)
SG (2) SG10201607976WA (cg-RX-API-DMAC10.html)
TW (1) TW201343164A (cg-RX-API-DMAC10.html)
UY (1) UY34720A (cg-RX-API-DMAC10.html)
WO (1) WO2013148690A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201407722B (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート,インコーポレイティド (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
US20240043499A1 (en) 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production
US12483171B2 (en) 2023-12-18 2025-11-25 Abb Schweiz Ag Plug and play solid state controller for high efficiency motors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466379A (zh) * 2006-06-12 2009-06-24 泰华制药工业有限公司 稳定的拉喹莫德的制剂
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
EP2653873B8 (en) 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
US20100260755A1 (en) * 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
EP3318249A1 (en) * 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
DK2533634T3 (en) * 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
CA2825009A1 (en) * 2011-01-25 2012-08-02 Novartis Ag Systems and methods for medical use of motion imaging and capture
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466379A (zh) * 2006-06-12 2009-06-24 泰华制药工业有限公司 稳定的拉喹莫德的制剂
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEFFREY A. COHEN: "The future of multiple sclerosis treatment", 《JOURNAL OF THE NEUROLOGICAL SCIENCES》 *
LUDWING KAPPOS等: "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre,randomised, double-blind, placebo-controlled phase IIb study", 《THE LANCET》 *
张金妮等: "多发性硬化早期表现为临床孤立综合征79 例临床分析", 《中国神经免疫学和神经病学杂志》 *

Also Published As

Publication number Publication date
SG10201607976WA (en) 2016-11-29
US20180050031A1 (en) 2018-02-22
JP2017200927A (ja) 2017-11-09
EP2830623A1 (en) 2015-02-04
MX2014011616A (es) 2014-10-17
US20130259856A1 (en) 2013-10-03
AU2013239850A1 (en) 2014-11-06
ZA201407722B (en) 2016-06-29
WO2013148690A1 (en) 2013-10-03
US20170319570A1 (en) 2017-11-09
AU2018200065A1 (en) 2018-02-01
CN104470520A (zh) 2015-03-25
UY34720A (es) 2013-10-31
TW201343164A (zh) 2013-11-01
SG11201405755QA (en) 2014-10-30
US20150119420A1 (en) 2015-04-30
AR090491A1 (es) 2014-11-19
US20160000774A1 (en) 2016-01-07
JP2015512406A (ja) 2015-04-27
EA201491773A1 (ru) 2015-02-27
HK1205941A1 (en) 2015-12-31
IL234687A0 (en) 2014-11-30
EP2830623A4 (en) 2015-09-02
CA2868259A1 (en) 2013-10-03
US20170224675A1 (en) 2017-08-10
KR20150003765A (ko) 2015-01-09

Similar Documents

Publication Publication Date Title
US20180050031A1 (en) Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate
US8889627B2 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US20160361352A1 (en) Treatment of Multiple Sclerosis With Combination of Laquinimod and Glatiramer Acetate
US20150056281A1 (en) Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta
US20160235735A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
US20170007596A1 (en) Treatment of multiple sclerosis with combination of laquinimod and flupirtine
US20170304253A1 (en) Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis
US20160296513A1 (en) Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
US20160317525A1 (en) Treatment of multiple sclerosis with combination of laquinimod and teriflunomide
HK1224600A (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
HK1224600A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1224600

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160817

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1224600

Country of ref document: HK